Strategic Alliance Partnership | Contemporary Pediatrics connects pediatricians with peer-reviewed articles, guideline updates, and practice strategies for real-world clinical application.

Check out the top 5 pharmacology articles of 2025. The increasing availability of at-home infant cardiorespiratory monitoring devices has raised important questions for pediatric practice regarding ...

Join us for a recap of some of our top dermatology puzzler cases from 2025. A 21-year-old primigravida woman presented to the hospital in preterm labor, with an otherwise uneventful pregnancy except ...

Prenatal exposure to hot, humid conditions was associated with significantly reduced child growth, with effects far greater than heat alone. Extreme heat is a well-recognized health risk during ...

Approval of the expanded indication fullfilled all post-marketing requirements outlined in the original approval letter. On December 23, 2025, the FDA approved an expanded indication for furosemide ...

“We started out 2025 with an environment that was rife with myths and disinformation," said Robert H. Hopkins, Jr., MD, in this year-end recap of 2025 and the pediatric vaccine landscape. Pediatric ...

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades. Phase 3 data demonstrated noninferiority to ceftriaxone plus ...

Waskyra becomes the first FDA-approved gene therapy for Wiskott-Aldrich syndrome, offering hope to patients with this rare immunodeficiency. On December 9, 2025, the FDA approved Waskyra ...

Following an updated policy from the American Academy of Child and Adolescent Psychiatry, Joshua Feder, MD, explains why providers should present DRBIs and NDBIs as options for autism care.

“We took a different approach by looking at colonizing bacteria, and we found vaccination reduced antimicrobial resistance through a completely different mechanism," said Brooke Ramay, lead author of ...

"For those not receiving the HBV birth dose, it is suggested that the initial dose is administered no earlier than 2 months of age," reads part of vote 1. The Centers for Disease Control and ...

New US modeling study results find nirsevimab would avert the most infant RSV-LRTD events and hospitalizations compared with clesrovimab or RSVpreF maternal vaccination. Nirsevimab provided the ...